Outlook Therapeutics, Inc. OTLKW 深 滬

Outlook Therapeutics Announces New Equity Financing Transaction

Outlook Therapeutics ( ($OTLK) ) has issued an update. On April 22, 2026, Outlo...

04-24 05:54

Outlook Therapeutics announces $5M registered direct offering priced at-the-market

Outlook Therapeutics (OTLK) on Wednesday said it has entered into an agreement for the purchase and sale of an aggregate of 16.12M shares of its common stock at an offering price of $0.31 per share of...

04-22 20:48

Outlook Therapeutics Completes Federal Dispute Resolution Meeting With The Office Of New Drugs At FDA For Regulatory Nod For ONS-5010 / LYTENAVA

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has completed its Federal

04-21 21:15

Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug

Outlook Therapeutics files FDA dispute on ONS-5010 after CRL citing effectiveness concerns; meeting with agency official set for April 2026.

04-08 02:11

Outlook Therapeutics stock slides after pricing $5M offering

Outlook Therapeutics (OTLK) shares fell 34% in premarket trading Tuesday after the company priced a public offering. The biopharma firm is selling 20M shares along with warrants to buy up to 20M share...

03-24 19:11

Why Paranovus Entertainment Technology Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket

PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global Partners and other stocks moved.

03-24 17:31

Outlook Therapeutics launches public offering; shares down

Outlook Therapeutics (OTLK) has initiated a best-efforts public offering of common stock and accompanying warrants. The offering may include pre-funded warrants in place of common stock. The offering ...

03-24 05:41

Outlook Therapeutics Reveals Proposed Public Offering; No Size Disclosed

Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced a best-efforts

03-24 05:35

Outlook Therapeutics Announces Proposed Public Offering

Outlook Therapeutics, Inc. announced the launch of a public offering of its common stock and warrants, with proceeds intended for working capital and general corporate purposes. H.C. Wainwright & Co. serves as the exclusive placement agent. The offering is under a shelf registration statement, and a prospectus supplement will be filed with the SEC. The company, focused on enhancing care for retina diseases, aims to commercialize its ophthalmic be...

03-23 21:30

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

03-16 12:05